Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Disease Severity
100%
Meta-analysis
100%
Systematic Meta-analysis
100%
COVID-19
100%
Renin-angiotensin System Inhibitors
100%
Angiotensin-converting Enzyme Inhibitor (ACEi)
83%
Angiotensin Receptor Blockers
83%
Confidence Interval
66%
Hazard Ratio
33%
Odds Ratio
33%
Critical Disease
33%
Quality Assessment
16%
Hypertension
16%
Overall Risk
16%
Systematic Literature Review
16%
Clinical Indications
16%
Qualitative Synthesis
16%
Risk of Harm
16%
Mortality Outcomes
16%
Random Effects Model
16%
Renin-angiotensin System
16%
Severe Course
16%
Medicine and Dentistry
Meta-Analysis
100%
Systematic Review
100%
Disease Severity
100%
COVID-19
100%
Renin-Angiotensin System Inhibitor
100%
ACE Inhibitor
83%
Angiotensin Receptor Antagonist
83%
Diseases
33%
Hazard Ratio
33%
Odds Ratio
33%
Effect Size
16%
Random Effects Model
16%
Renin Angiotensin Aldosterone System
16%
Neuroscience
Systematic Review
100%
Meta-Analysis
100%
Angiotensin
100%
Renin
100%
Coronavirinae
100%
Coronavirus
100%
ACE Inhibitor
83%
Angiotensin Receptor
83%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
100%
Coronavirinae
100%
Disease Severity
100%
Renin-Angiotensin System Inhibitor
100%
Dipeptidyl Carboxypeptidase Inhibitor
62%
Angiotensin Receptor Antagonist
62%
Random Effects Model
12%
Angiotensin
12%
Renin
12%